Friday, September 7, 2012

Stealthy Didimi pushes cells back to the starting line

If twins know each other better than anyone else, leaders of Didimi Inc. are counting on the same holding true for our cells. One of the companies on the growing roster of the QB3 East Bay Innovation Center, Didimi is focusing on a way to regenerate insulin-producing islet cells — from a patient’s own or someone else’s cells — as a treatment for Type 1 diabetes. Call it a cellular do-over or a scientific version of “Groundhog Day” with some potentially stunning implications.

No comments:

Post a Comment